Business Strategy Expertise

Whether you are just starting out or trying to evolve an established life science business, today’s investors are more aware than ever that sound strategy is essential. A mix of R&D productivity pressure, tightening regulations, scientific innovation and a market demanding value evidence is challenging companies to think carefully about their goals and priorities. Our life science consultants have rich experience in strategic planning with companies at all stages of corporate development.

  • Craft a business case for company strategy
  • Develop your corporate pitch deck for investors
  • Prioritize R&D spending through portfolio review and pipeline planning
  • Build a business unit or technology strategy plan

Both external investors and internal sponsors in a business draw confidence from quality business planning and can tell whether a business plan or strategy is realistic. Our subject matter experts have launched, grown, and sold companies. They have successfully raised capital and advised investors and company boards about funding decisions. Let us help you consider all relevant strategic options for your business or your pipeline, analyze them thoroughly, and present a clear and well-reasoned case that your strategy is the right one.


Featured Case Study: Business plan for medical device start-up



Our client was a start-up looking to raise external venture capital funding for development of a biosensor for early detection of opioid overdose. The company had drafted a business plan with which to engage investors. Alacrita was asked to review and refine the business plan, with a particular emphasis on the target market, product value proposition, and market access plan.



Our consultant prioritized the target patient segments and settings of care for the device, framed the value proposition around the needs of key market stakeholders, and aligned these with the company's clinical development and market access plans. Our consultants brought direct experience in the commercialization of prescription opioids, deep knowledge of the opioid crisis and an expertise in developing and launching medical devices in the US market.

Our expert and investor network was able to sanity check further the plan for the device and its value proposition. The business plan review resulted in the client changing their clinical development and investment staging plans. Based on its importance to investors and payers, the client framed its clinical proof-of-concept plans around showing that the device could give an early enough warning to deliver on its value proposition.